Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.43 |
| ▸ | CDC25B | P30305 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 4/20 | 0.38 |
| ▸ | GSK3B | P49841 | 5/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648661 | 0.88 | HPGD (0.53) | PTPN1CDC25BHPGDPOLBPKM | |
| SCHEMBL652694 | 0.86 | GSK3B (0.47) | PTPN1CDC25BHPGDPOLBPKM | |
| SCHEMBL10176413 | 0.80 | PTPN1 (0.44) | PTPN1CDC25BCNR1HPGDPOLB | |
| SCHEMBL653362 | 0.71 | MAPT (0.45) | CDC25BHPGDPOLB | |
| SCHEMBL648825 | 0.69 | DYRK3 (0.36) | CNR1HPGDPOLBPIM1PIM2 | |
| SCHEMBL650134 | 0.69 | AKR1B1 (0.39) | HPGDPOLBPIM1PIM2DYRK1A | |
| SCHEMBL651355 | 0.67 | PTPN1 (0.46) | PTPN1CDC25BHPGDPOLBPKM | |
| SCHEMBL650769 | 0.67 | MAPT (0.39) | HPGDPOLB | |
| SCHEMBL651474 | 0.67 | NOS3 (0.35) | CDC25BCNR1POLB | |
| SCHEMBL651037 | 0.66 | NOS3 (0.36) | CNR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135989-A1 | AZAINDOLE DERIVATIVE | CRYSTALGENOMICS, INC. (KR) | 2012-05-31 | — | — | US | disclosed |
| EP-2423204-A1 | THIAZOLIDINONE DERIVATIVE | SBI Biotech Co., Ltd. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-8119812-B2 | Thiazolidinone derivative | SBI BIOTECH CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | SBI BIOTECH CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
| EP-0864568-B1 | Agents for treatment of cardiac diseases | KUREHA CHEMICAL IND CO LTD (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-6242445-B1 | CURATIVE EFFECTS FOR CARDIAC AND NEPHRIC DISEASES, ALTHOUGH HAVING LITTLE ACTION ON BLOOD-PRESSURE. | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 2001-06-05 | — | — | US | disclosed |
| US-6211175-B1 | P-AMINOMETHYLBENZOIC ACID DERIVATIVES; CARDIOVASCULAR DISORDERS; NONHYPOTENSIVE | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 2001-04-03 | — | — | US | disclosed |
| EP-1069113-A1 | BENZIMIDAZOLE DERIVATIVE | Kureha Chemical Industry Co., Ltd. (JP) | 2001-01-17 | — | — | EP | disclosed |
| EP-0807628-B1 | Aromatic compound and pharmaceutical composition | KUREHA CHEMICAL IND CO LTD (JP) | 2000-12-20 | — | — | EP | disclosed |
| US-5932575-A | Cardiac diseases improving agents | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1999-08-03 | — | — | US | disclosed |
| US-5863913-A | ALLEVIATION OF RENAL DYSFUNCTION WITHOUT AFFECTING BLOOD PRESSURE AT A LOW BLOOD CONCENTRATION. | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1999-01-26 | — | — | US | disclosed |
| EP-0864568-A1 | Agents for treatment of cardiac diseases | KUREHA CHEMICAL INDUSTRY CO., LTD. (JP) | 1998-09-16 | — | — | EP | disclosed |
| EP-0807628-A1 | Aromatic compound and pharmaceutical composition | Kureha Chemical Industry Co., Ltd. (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190299-A1 | THIAZOLIDINONE DERIVATIVE | CDC7, CDK17, CDCA2 | PTPN1 1863/4885CDC25B 59/4885CNR1 4723/4885 |
| US-20120135989-A1 | AZAINDOLE DERIVATIVE | CDC7, CDCA2, CDC5L | PTPN1 2296/4885CDC25B 22/4885CNR1 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.